Abstract
Background: Two main forms of amiodarone-induced thyrotoxicosis (AIT) exist: type 1 AIT is a condition of true hyperthyroidism developing in patients with pre-existing thyroid disorders, and usually requires thyroid ablative treatment. On the other hand, type 2 AIT is a form of destructive thyroiditis occurring in normal thyroids, the management of which usually consists in glucocorticoid treatment. Aim: To assess the long-term outcome of thyroid function in a prospective study of type 2 AIT patients, as compared to patients with De Quervain’s subacute thyroiditis (SAT). Patients and Methods: Sixty consecutive patients with type 2 AIT were evaluated during oral glucocorticoid treatment (oral prednisone 30 mg/day, gradually tapered and withdrawn over a 3-month period) and followed for 38±4 months (range 6–72) thereafter. Sixty consecutive patients with SAT, referred to our Institutes during the same period and treated with the same therapeutic schedule, served as controls. Results: Type 2 AIT patients were older (p<0.0001) and showed a larger male preponderance (M:F 3.6:1 vs 0.5:1, p<0.0001) than SAT patients. Mean serum free T4 (FT4) and free T3 (FT3) concentrations at diagnosis were increased in both conditions, but higher in type 2 AIT than in SAT (FT4 47.6±18.8 and 29.6±8.3 pmol/l, respectively, p<0.0001; FT3 15.4±7.0 and 11.2±3.0 pmol/l, respectively, p<0.001). Correction of thyrotoxicosis was obtained in all patients in both groups, but restoration of euthyroidism occurred earlier in SAT than in type 2 AIT (p=0.006). Ten type 2 AIT patients (17%) and 3 SAT patients (5%, p<0.03) became permanently hypothyroid after glucocorticoid withdrawal and required levothyroxine replacement. Conclusions: A relevant proportion of type 2 AIT patients develop permanent hypothyroidism after correction of thyrotoxicosis. Thus, periodic surveillance of thyroid status is required after type 2 AIT.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Martino E, Bartalena L, Bogazzi F, Braverman LE. Amiodarone and the thyroid. Endocr Rev 2001, 22: 240–54.
Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001, 4: 116–30.
Wiersinga WM. Amiodarone and the thyroid. In: Weetman, AP, Grossman A eds. Pharmacotherapeutics of the Thyroid Gland. Berlin: Springer Verlag 1997, 225–87.
Iudica-Souza C, Burch HB. Amiodarone-induced thyroid dysfunction. The Endocrinologist 1999, 9: 216–27.
Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-induced thyroid dysfunction. Risk factors in adults with congenital heart disease. Circulation 1999, 100: 149–54.
Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984, 101: 28–34.
Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results from a prospective study. J Clin Endocrinol Metab 1996, 81: 2930–3.
Bartalena L, Bogazzi F, Martino E. Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin Endocrinol (Oxf) 2002, 56: 23–4.
Bartalena L, Wiersinga WM, Tanda ML, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 2004, 61: 494–502.
Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler sonography rapidly differentiates type I andtype II amiodarone-induced thyrotoxicosis. Thyroid 1997, 7: 541–5.
Eaton SEM, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002, 56: 33–8.
Bogazzi F, Martino E, Dell’Unto E, et al. Thyroid color flow Doppler sonography and radioiodine uptake in 51 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003, 26: 635–40.
Vitti P, Rago T. Thyroid ultrasound as a predictor of thyroid disease. J Endocrinol Invest 2003, 26: 686–9.
Bogazzi F, Bartalena L, Brogioni S, et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone level: studies in vivo by color flow Doppler sonography. Eur J Endocrinol 1999, 140: 452–6.
Chopra IJ, Baber, K. Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. J Clin Endocrinol Metab 2001, 86: 4707–10.
Trip MD, Wiersinga WM. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991, 91: 603–6.
Leger AF, Massin JP, Laurent MF. Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases. Eur J Clin Invest 1984, 14: 449–57.
Wimpfheimer C, Staubli M, Schadelin J, Studel H. Prednisone in amiodarone-induced thyrotoxicosis. Br Med J 1982, 284: 1835–6.
Broussolle C, Ducottet X, Martin C, et al. Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. J Endocrinol Invest 1989, 12: 37–42.
Bonnyns M, Sterling I, Renard M. Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug. Acta Cardiol 1989, 44: 235–43.
Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986, 9: 201–7.
Williams M, Lo Gerfo P. Thyrodectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 2002, 12: 523–5.
Bogazzi F, Miccoli P, Berti P, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone induced thyrotoxicosis. Surgery 2002, 132: 1114–8.
Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 2002, 105: 1275–7.
Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003, 348: 2646–51.
Fatourechi V, Aniszewski JP, Fatuorechi GP, Atkinson EJ, Jacobs SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmstedt County, Minnesota. J Clin Endocrinol Metab 2003, 88: 2100–5.
Lio S, Pontecorvi A, Caruso M, Monaco F, D’Armiento M. Transitory subclinical or permanent hypothyroidism in the course of subacute (De Quervain) thyroiditis. Acta Endocrinol (Copenh) 1984, 106: 67–70.
Roti E, Minelli R, Gardini E, et al. Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1992, 75: 1273–7.
Roti E, Minelli R, Gardini E, et al. Impaired intrathyroidal iodine organification and iodine-induced hypothyroidim in euthyroid women with a previous episode of postpartum thyroiditis. J Clin Endocrinol Metab 1991, 73: 958–63.
Roti E, Minelli R, Gardini E, Bianconi L, Breverman LE. Iodine-induced hypothyroidism in euthyroid subjects with a previous episode of subacute thyroiditis. J Clin Endocrinol Metab 1990, 70: 1581–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bogazzi, F., Dell’Unto, E., Tanda, M.L. et al. Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. J Endocrinol Invest 29, 694–699 (2006). https://doi.org/10.1007/BF03344178
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344178